Form 8-K Mirati Therapeutics, For: May 24
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
58,900$
0,17%
Echtzeit-Aktienkurs Mirati Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Mirati Therapeutics Inc. Aktie
Form 8-K Mirati Therapeutics, For: May 11
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development…
Form 10-Q Mirati Therapeutics, For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial…
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial…
Strength Seen in Mirati (MRTX): Can Its 13.5% Jump Turn into More Strength?
Mirati (MRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…
Mirati (MRTX) Reports Q4 Loss, Misses Revenue Estimates
Mirati (MRTX) delivered earnings and revenue surprises of 6.15% and 75.17%, respectively, for the quarter ended December 2022. Do the…
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
SAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial…
Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference
SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate at the…
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023
SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results…
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that…
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two…
Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage
Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate…
Insiderhandel: Aufsichtsrat verkauft Aktien von Mirati Ther im Wert von 113.704$
Cherrington, Julie M. - Aufsichtsrat - Tag der Transaktion: 2023-01-18...…
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
IND demonstrates Miratis leadership in KRAS, representing the Companys third KRAS or KRAS-signaling program to enter clinical development SAN DIEGO,…
Insiderhandel: EVP, Chief Scientific Officer verkauft Aktien von Mirati Ther im Wert von 95.142$
Christensen, Jamie - Vorstand - Tag der Transaktion: 2023-01-17...…
Insiderhandel: Chief Executive Officer verkauft Aktien von Mirati Ther im Wert von 134.715$
Meek, David D. - Vorstand - Tag der Transaktion: 2023-01-17...…
Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Mirati Ther im Wert von 66.366$
Hickey, Benjamin - Vorstand - Tag der Transaktion: 2023-01-17...…
Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Mirati Ther im Wert von 94.733$
Hickey, Benjamin - Vorstand - Tag der Transaktion: 2023-01-09...…
Form 8-K Mirati Therapeutics, For: Jan 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that…
Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm
Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ:…
Insiderhandel: President,Founder,Head of R&D verkauft Aktien von Mirati Ther im Wert von 169.997$
Baum, Charles M. - Vorstand - Tag der Transaktion: 2023-01-04...…
Insiderhandel: EVP, Chief Scientific Officer verkauft Aktien von Mirati Ther im Wert von 90.823$
Christensen, Jamie - Vorstand - Tag der Transaktion: 2023-01-04...…